Achtelik M, Pethig K, Schäfers H J, Borst H G
Division of Thoracic and Cardiovacular Surgery, Hannover Medical School, Germany.
J Heart Valve Dis. 1996 Nov;5 Suppl 3:S314-6.
Due to improved hemodynamic properties stentless bioprostheses represent a new therapeutic option in the surgical treatment of aortic valve disease.
Between February 1993 and June 1995 22 patients with a small aortic root regarded as suboptimal for a stented bioprosthesis (diameter < or = 23 mm, mean 21.6 +/- 1.9 mm) underwent aortic valve replacement with a Biocor stentless prosthesis. Mean age was 63.9 +/- 15.4 years (17-85 years). Valve size ranged from 21 to 27 mm (mean 25 mm) and exceeded the root diameter by 4 mm. As compared to a control group of patients with root enlargement (n = 10) total bypass time and cross-clamp time in the stentless group were significantly shorter (83.3 +/- 12.7 and 60.9 +/- 9.2 min versus 95.8 +/- 27.1 and 69.5 +/- 16.5 min, p = 0.054 and p < 0.05), respectively.
Three patients died postoperatively unrelated to the choice of valve. There were no late deaths. No thromboembolic or bleeding events were observed. Follow up data are available over a period of 1-25 months (mean 12.5 months, median 16 months). Echocardiographic evaluation revealed no aortic regurgitation; mean valve gradients were 9.9 +/- 4.1 mmHg (peak 19.2 +/- 6.0 mmHg). For specific root diameters these gradients were compared to established data for Hancock bioprostheses demonstrating significant differences in transvalvular gradients between the two valve designs for given root diameters. Unloading the left ventricle resulted in regression of left ventricular hypertrophy (decrease in wall thickness from 13.6 +/- 1.7 mm to 11.2 +/- 2.0 mm). Exercise capacity improved from NYHA III-IV preoperative to I-II postoperative.
In patients with a small aortic root stentless valves represent a new option. Compared to root enlargement with standard bioprosthesis myocardial ischemia is shorter and implantation of larger valve sizes results in superior hemodynamics.
由于血流动力学特性的改善,无支架生物瓣膜在主动脉瓣疾病的外科治疗中代表了一种新的治疗选择。
1993年2月至1995年6月期间,22例主动脉根部较小、被认为不适合植入有支架生物瓣膜(直径≤23mm,平均21.6±1.9mm)的患者接受了使用Biocor无支架瓣膜的主动脉瓣置换术。平均年龄为63.9±15.4岁(17 - 85岁)。瓣膜尺寸范围为21至27mm(平均25mm),比根部直径大4mm。与根部扩大的对照组患者(n = 10)相比,无支架组的总体外循环时间和主动脉阻断时间明显更短(分别为83.3±12.7和60.9±9.2分钟,而对照组为95.8±27.1和69.5±16.5分钟,p = 0.054和p < 0.05)。
3例患者术后死亡,与瓣膜选择无关。无晚期死亡病例。未观察到血栓栓塞或出血事件。随访数据的时间跨度为1至25个月(平均12.5个月,中位数16个月)。超声心动图评估显示无主动脉瓣反流;平均瓣膜压差为9.9±4.1mmHg(峰值19.2±6.0mmHg)。对于特定的根部直径,将这些压差与Hancock生物瓣膜的既定数据进行比较,结果表明在给定根部直径的情况下,两种瓣膜设计的跨瓣压差存在显著差异。左心室负荷减轻导致左心室肥厚消退(室壁厚度从13.6±1.7mm降至11.2±2.0mm)。运动能力从术前的纽约心脏协会(NYHA)III - IV级改善至术后的I - II级。
对于主动脉根部较小的患者,无支架瓣膜是一种新的选择。与使用标准生物瓣膜进行根部扩大相比,心肌缺血时间更短,植入较大尺寸的瓣膜可带来更好的血流动力学效果。